Skip to NavigationSkip to content

Business Services

Allarity Therapeutics partners with Lonza to manufacture Dovitinib

Allarity Therapeutics, a clinical-stage precision medicine company, has announced its collaboration with biopharma partner Lonza to manufacture dovitinib. Dovitinib targets metastatic renal cell carcinoma (RCC) with other potential uses in liver cancer, breast cancer and various solid tumours.

The agreement between the two companies aims to commence manufacturing of dovitinib in 2022, and will be brought to the market following Allarity’s need for regulatory approvals and protocol.   

Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on Friday suggest that protection from their respective COVID-19 vaccines wanes over time. This comes as the FDA consider the approval of a booster programme in the US.

Moderna shared new data about its vaccine on Wednesday. In addition to the jab being highly effective against new strains, the company released data from their Phase III COVE study suggesting that a booster dose of the vaccine will support greater efficacy for the population.

CPhI Worldwide

Malaria sickness could be cut by 70%, study finds

Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) have found a new approach to protecting young African children from malaria could reduce deaths and illness from the disease by 70%.

RTS,S vaccines, created by GSK over 20 years ago, were administered before the worst season, in addition to preventative drugs, to 6,000 children aged under 17 months in Burkina Faso and Mali.

Stelis Biopharma appoints Mark Womack as new CEO

Published on: 25/08/21

Stelis Biopharma Limited has announced the appointment of Mark W Womack as the new Chief Executive Officer.

Womack is also the Managing Director designate and shall be inducted to the Board later, subject to necessary statutory clearances and processes.

Arun Kumar, Founder, Strides Group, said, "We are delighted to onboard Mark as the new CEO of Stelis. Mark's strong background in commercial leadership, rich management consulting experience, and network within the biotech CDMO space make him exceptionally well suited to drive this transition for Stelis.”

PureTech appoints Julie Krop as Chief Medical Officer

Published on: 25/08/21

Clinical-stage biotherapeutics company PureTech has appointed Julie Krop as Chief Medical Officer.

Krop will oversee all clinical development, Regulatory, CMC, and medical affairs for the company’s advancing Wholly Owned Pipeline.

Daphne Zohar, Founder and Chief Executive Officer of PureTech, said: "Julie is a biopharmaceutical industry veteran with a wide breadth of expertise across multiple therapeutic areas and orphan indications.

Tracey Lodie appointed Chief Scientific Officer of Quell Therapeutics

Published on: 25/08/21

Quell Therapeutics has announced the appointment of Tracey Lodie as Chief Scientific Officer.

Dr Lodie brings to Quell more than 20 years of experience in the biopharmaceutical industry focused on the discovery and development of cell therapies and novel biologics in the areas of autoimmunity, transplant biology, and immune-oncology.

Dr Lodie joins Quell from Gamida Cell, a clinical-stage, Nasdaq-listed cell therapy company, where she served as CSO with responsibility for strategic oversight of its entire cell therapy pipeline.

RareCan appoints Dr Anita Cooper as Non-Executive Director

Published on: 25/08/21

Cancer research company RareCan has appointed Dr Anita Cooper as Non-Executive Director.

Cooper has over 30 years’ experience in global business and is currently a Non-Executive Director for Simbec-Orion, a leading Clinical Research Organisation.

Piers Kotting, CEO of RareCan, commented: “We are thrilled to welcome Anita to the Board of RareCan. Anita’s wealth of industry experience will help us to accelerate rare cancer research by maximising the value of RareCan to both the global life sciences and pharmaceutical services industries.”

Laura Steele appointed President and General Manager for Lilly UK

Published on: 25/08/21

Eli Lilly and Company have announced that Laura Steele has been appointed President and General Manager (GM) for UK, Ireland & Northern Europe. Laura succeeds Ashley Diaz-Granados, who assumes a senior role within Lilly USA leading the company’s Immunology division.

Laura will lead Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology, and Neuroscience.

Medical cannabis: The next innovation in oncology?

Published on 25/08/21 at 10:36am

The market for medical cannabis has been growing steadily over the last decade, but it may be on the cusp of a breakthrough in oncology. Kat Jenkins takes a look at some of the cutting-edge cannabis research underway, speaking to those working at the forefront of the field to explore this evolving cancer treatment of the future

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches